Next Article in Journal
Controlled Size Oils Based Green Fabrication of Silver Nanoparticles for Photocatalytic and Antimicrobial Application
Next Article in Special Issue
Automating Predictive Phage Therapy Pharmacology
Previous Article in Journal
Impact of SARS-CoV-2 Preventive Measures against Healthcare-Associated Infections from Antibiotic-Resistant ESKAPEE Pathogens: A Two-Center, Natural Quasi-Experimental Study in Greece
Previous Article in Special Issue
Vibrio Phage VMJ710 Can Prevent and Treat Disease Caused by Pathogenic MDR V. cholerae O1 in an Infant Mouse Model
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Bacteriophage–Antibiotic Combination Therapy against Pseudomonas aeruginosa

by
Guillermo Santamaría-Corral
1,
Abrar Senhaji-Kacha
1,2,
Antonio Broncano-Lavado
1,
Jaime Esteban
1,2,* and
Meritxell García-Quintanilla
1,2
1
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Av. Reyes Católicos 2, 28040 Madrid, Spain
2
CIBERINFEC—Infectious Diseases CIBER, 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(7), 1089; https://doi.org/10.3390/antibiotics12071089
Submission received: 4 April 2023 / Revised: 19 June 2023 / Accepted: 20 June 2023 / Published: 22 June 2023

Abstract

Phage therapy is an alternative therapy that is being used as the last resource against infections caused by multidrug-resistant bacteria after the failure of standard treatments. Pseudomonas aeruginosa can cause pneumonia, septicemia, urinary tract, and surgery site infections mainly in immunocompromised people, although it can cause infections in many different patient profiles. Cystic fibrosis patients are particularly vulnerable. In vitro and in vivo studies of phage therapy against P. aeruginosa include both bacteriophages alone and combined with antibiotics. However, the former is the most promising strategy utilized in clinical infections. This review summarizes the recent studies of phage-antibiotic combinations, highlighting the synergistic effects of in vitro and in vivo experiments and successful treatments in patients.
Keywords: Pseudomonas aeruginosa; treatment; bacteriophage; combination Pseudomonas aeruginosa; treatment; bacteriophage; combination

Share and Cite

MDPI and ACS Style

Santamaría-Corral, G.; Senhaji-Kacha, A.; Broncano-Lavado, A.; Esteban, J.; García-Quintanilla, M. Bacteriophage–Antibiotic Combination Therapy against Pseudomonas aeruginosa. Antibiotics 2023, 12, 1089. https://doi.org/10.3390/antibiotics12071089

AMA Style

Santamaría-Corral G, Senhaji-Kacha A, Broncano-Lavado A, Esteban J, García-Quintanilla M. Bacteriophage–Antibiotic Combination Therapy against Pseudomonas aeruginosa. Antibiotics. 2023; 12(7):1089. https://doi.org/10.3390/antibiotics12071089

Chicago/Turabian Style

Santamaría-Corral, Guillermo, Abrar Senhaji-Kacha, Antonio Broncano-Lavado, Jaime Esteban, and Meritxell García-Quintanilla. 2023. "Bacteriophage–Antibiotic Combination Therapy against Pseudomonas aeruginosa" Antibiotics 12, no. 7: 1089. https://doi.org/10.3390/antibiotics12071089

APA Style

Santamaría-Corral, G., Senhaji-Kacha, A., Broncano-Lavado, A., Esteban, J., & García-Quintanilla, M. (2023). Bacteriophage–Antibiotic Combination Therapy against Pseudomonas aeruginosa. Antibiotics, 12(7), 1089. https://doi.org/10.3390/antibiotics12071089

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop